NYSEAMERICAN:LCTX - Lineage Cell Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.60
  • Forecasted Upside: 156.88 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$2.18
▼ -0.11 (-4.80%)
1 month | 3 months | 12 months
Get New Lineage Cell Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LCTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LCTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.60
▲ +156.88% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lineage Cell Therapeutics in the last 3 months. The average price target is $5.60, with a high forecast of $7.00 and a low forecast of $4.00. The average price target represents a 156.88% upside from the last price of $2.18.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Lineage Cell Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
4/7/2021Chardan CapitalReiterated RatingBuy$4.00
i
3/30/2021Cantor FitzgeraldInitiated CoverageOverweight$6.00
i
Rating by K. Kluska at Cantor Fitzgerald
3/12/2021Maxim GroupReiterated RatingBuy$5.00
i
2/24/2021HC WainwrightReiterated RatingBuy$7.00
i
10/12/2020Dawson JamesReiterated RatingBuy$6.00
i
9/17/2020Noble FinancialInitiated CoverageOutperform
i
9/2/2020HC WainwrightReiterated RatingBuy
i
Rating by Joseph Pantginis at HC Wainwright
8/7/2020Maxim GroupInitiated CoverageBuy$3.00
i
Rating by Naureen Quibria at Maxim Group
6/26/2020Maxim GroupInitiated CoverageBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
6/10/2020HC WainwrightReiterated RatingBuy
i
Rating by Joseph Pantginis at HC Wainwright
6/2/2020Maxim GroupReiterated RatingBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
5/12/2020Chardan CapitalReiterated RatingBuy
i
5/9/2020Maxim GroupInitiated CoverageBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
5/5/2020HC WainwrightReiterated RatingBuy$4.00
i
Rating by Joseph Pantginis at HC Wainwright
3/13/2020HC WainwrightReiterated RatingBuy
i
Rating by J. Pantginis at HC Wainwright
2/10/2020HC WainwrightReiterated RatingBuy$4.00
i
Rating by Joseph Pantginis at HC Wainwright
1/3/2020HC WainwrightReiterated RatingBuy$4.00
i
Rating by Joseph Pantginis at HC Wainwright
11/13/2019HC WainwrightReiterated RatingBuy$4.00
i
Rating by Joseph Pantginis at HC Wainwright
10/15/2019Maxim GroupSet Price TargetBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
8/22/2019Chardan CapitalReiterated RatingBuy
i
Rating by K. Nakae at Chardan Capital
8/9/2019Maxim GroupSet Price TargetBuy$3.00
i
Rating by Jason McCarthy at Maxim Group
(Data available from 4/19/2016 forward)
Lineage Cell Therapeutics logo
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $2.18
$2.18
$2.33

50 Day Range

MA: $1.76
$1.65
$1.93

52 Week Range

Now: $2.18
$0.70
$3.13

Volume

638,576 shs

Average Volume

1,782,797 shs

Market Capitalization

$352.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Lineage Cell Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Lineage Cell Therapeutics in the last year: Cantor Fitzgerald, Chardan Capital, Dawson James, HC Wainwright, Maxim Group, Noble Financial, and Zacks Investment Research.
View the latest analyst ratings for LCTX.

What is the current price target for Lineage Cell Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Lineage Cell Therapeutics in the last year. Their average twelve-month price target is $5.60, suggesting a possible upside of 156.9%. HC Wainwright has the highest price target set, predicting LCTX will reach $7.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $4.00 for Lineage Cell Therapeutics in the next year.
View the latest price targets for LCTX.

What is the current consensus analyst rating for Lineage Cell Therapeutics?

Lineage Cell Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LCTX will outperform the market and that investors should add to their positions of Lineage Cell Therapeutics.
View the latest ratings for LCTX.

What other companies compete with Lineage Cell Therapeutics?

How do I contact Lineage Cell Therapeutics' investor relations team?

Lineage Cell Therapeutics' physical mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The company's listed phone number is 510-871-4188 and its investor relations email address is [email protected] The official website for Lineage Cell Therapeutics is www.lineagecell.com.